Plant Name: Cassia occidentalis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.611E-08 | 3.507E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.765E-07 | 1.922E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 9.215E-07 | 5.017E-03 | CSNK2A1, ELANE, ESR1, HIF1A, MAPK1, PIM1, THPO, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 9.167E-07 | 5.017E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0051173; positive regulation of nitrogen compound metabolic process | 2.628E-06 | 9.969E-03 | ALOX15, BLM, CSNK2A1, ELANE, ESR1, ESR2, HIF1A, MAPK1, MAPT, NFKB1, THPO, TSHR |
| BP | GO:0009987; cellular process | GO:0009966; regulation of signal transduction | 4.577E-06 | 9.969E-03 | ALOX15, BLM, CSNK2A1, ELANE, ESR1, ESR2, HIF1A, LMNA, MAPK1, MAPT, NFKB1, THPO |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.930E-06 | 9.969E-03 | CSNK2A1, HIF1A, MAPT |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 4.736E-06 | 9.969E-03 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 5.494E-06 | 9.969E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.494E-06 | 9.969E-03 | CYP2C9, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.361E-08 | 1.796E-06 | CYP2C9; ALOX15; CYP3A4; CYP2C19 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.744E-07 | 3.791E-05 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.385E-06 | 1.489E-04 | CYP2C9; ALOX15; MAPK1; CYP2C19 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.059E-05 | 6.795E-04 | PIM1; MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.653E-05 | 7.005E-04 | CYP2C9; ALOX15; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.660E-05 | 8.053E-04 | CYP2C9; CYP3A4; CYP2C19 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.142E-04 | 1.598E-03 | PIM1; MAPK1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.076E-04 | 1.598E-03 | MAPK1; ESR1; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.139E-05 | 1.158E-03 | CYP2C9; CYP3A4; CYP2C19 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.211E-04 | 1.598E-03 | MAPK1; HIF1A; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.811E-04 | 2.173E-03 | MAPK1; ESR1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.996E-04 | 3.296E-03 | LMNA; MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.110E-04 | 5.189E-03 | MAPK1; MAPT; HSD17B10 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.855E-04 | 7.793E-03 | MAPK1; HIF1A; ESR1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.360E-04 | 7.793E-03 | MAPK1; NFKB1; TSHR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.706E-03 | 1.036E-02 | MAPK1; MAPT; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.465E-03 | 1.036E-02 | MAPK1; HIF1A |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.323E-03 | 1.036E-02 | MAPK1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.769E-03 | 1.036E-02 | MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.769E-03 | 1.036E-02 | MAPK1; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.716E-03 | 1.036E-02 | CYP2C9; CYP3A4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.634E-03 | 1.159E-02 | PIM1; MAPK1; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.822E-03 | 1.036E-02 | MAPK1; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.159E-03 | 1.036E-02 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.716E-03 | 1.036E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.159E-03 | 1.036E-02 | MAPK1; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.159E-03 | 1.036E-02 | CYP2C9; CYP3A4 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.159E-03 | 1.036E-02 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.187E-03 | 1.315E-02 | MAPK1; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.217E-03 | 1.036E-02 | CSNK2A1; MAPK1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.067E-03 | 1.715E-02 | CYP2C9; ALOX15; CYP2C19; CYP3A4; HSD17B10 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.083E-03 | 1.585E-02 | MAPK1; HIF1A |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 4.323E-03 | 1.585E-02 | MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.277E-03 | 1.036E-02 | MAPK1; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.939E-03 | 1.823E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.486E-03 | 1.601E-02 | MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.822E-03 | 1.675E-02 | MAPK1; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.474E-03 | 1.390E-02 | CSNK2A1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.980E-03 | 1.269E-02 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 4.323E-03 | 1.585E-02 | MAPK1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.527E-03 | 1.795E-02 | MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.711E-03 | 1.795E-02 | MAPK1; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 6.869E-03 | 2.044E-02 | MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.711E-03 | 1.795E-02 | MAPK1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 8.343E-03 | 2.343E-02 | MAPK1; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.276E-03 | 2.088E-02 | CSNK2A1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.970E-03 | 2.044E-02 | MAPK1; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 9.710E-03 | 2.670E-02 | THPO; PIM1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.181E-02 | 3.180E-02 | MAPK1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.219E-02 | 3.219E-02 | MAPK1; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.550E-02 | 3.790E-02 | CSNK2A1; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.594E-02 | 3.826E-02 | MAPK1; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.246E-02 | 3.224E-02 | ELANE; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.339E-02 | 3.336E-02 | MAPK1; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.312E-02 | 3.331E-02 | CSNK2A1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.932E-02 | 4.553E-02 | MAPK1; NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; HIF1A |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ELANE |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ELANE |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; ESR1; PIM1; MAPK1; NFKB1; HIF1A; CSNK2A1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| NA: NA | Menopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ELANE |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ELANE; ELANE |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |